{
    "Clinical Trial ID": "NCT00004092",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I (ACT)",
        "  Patients receive 41.25 mg/m2 of doxorubicin IV over 24 hours on days -9 to -6, 100 mg/kg of cyclophosphamide IV over 2 hours on day -5, and 725 mg/m2 of paclitaxel IV over 24 hours on day -4. PBSC are reinfused on days -2 and 0. G-CSF at 5 ug/kg IV is administered beginning on day 0 and continuing until blood counts recover.",
        "  filgrastim: Given IV or subcutaneously",
        "  cyclophosphamide: Given IV",
        "  doxorubicin hydrochloride: Given IV",
        "  paclitaxel: Given IV",
        "  peripheral blood stem cell transplantation: Patients receive autologous peripheral blood stem cells",
        "INTERVENTION 2: ",
        "  Arm II (STAMP V)",
        "  Patients receive cyclophosphamide 1.5 g/m2/day IV, carboplatin 200 mg/m2/day IV, and thiotepa 125 mg/m2/day IV over 24 hours on days -7 to -4. PBSC are reinfused on day -2 and 0 and G-CSF at 5ug/kg IV is administered as in arm I.",
        "  filgrastim: Given IV or subcutaneously",
        "  carboplatin: Given IV",
        "  cyclophosphamide: Given IV",
        "  thiotepa: Given IV",
        "  peripheral blood stem cell transplantation: Patients receive autologous peripheral blood stem cells"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically proven high-risk primary breast cancer with less than 60% chance of progression-free survival of 3 years from diagnosis",
        "  Stage II with at least 10 positive axillary nodes OR",
        "  Stage IIIA or IIIB",
        "  No histologically proven bone marrow metastasis",
        "  No CNS metastasis",
        "  Hormone receptor status:",
        "  Hormone receptor status known",
        "  PATIENT CHARACTERISTICS:",
        "  Age:",
        "  Physiological age 60 or under",
        "  Menopausal status:",
        "  Not specified",
        "Performance status:",
        "  Karnofsky 80-100%",
        "  Life expectancy:",
        "  See Disease Characteristics",
        "  Hematopoietic:",
        "  Neutrophil count at least 1,500/mm^3",
        "  Platelet count at least 100,000/mm^3",
        "  Hepatic:",
        "  Bilirubin no greater than 1.5 mg/dL",
        "  SGOT or SGPT no greater than 2 times upper limit of normal",
        "  Hepatitis B antigen negative",
        "  Renal:",
        "  Creatinine no greater than 1.2 mg/dL",
        "  Creatinine clearance at least 70 mL/min",
        "  No prior hemorrhagic cystitis",
        "  Cardiovascular:",
        "  Ejection fraction at least 55% by MUGA",
        "  No prior significant valvular heart disease or arrhythmia",
        "  Pulmonary:",
        "  FEV_1 at least 60% of predicted",
        "  pO_2 at least 85 mm Hg on room air",
        "  pCO_2 at least 43 mm Hg on room air",
        "  DLCO at least 60% lower limit of predicted",
        "  Other:",
        "  No other prior malignancy except squamous cell or basal cell skin cancer or stage I or carcinoma in situ of the cervix",
        "  No CNS dysfunction that would preclude compliance",
        "  HIV negative",
        "  No sensitivity to E. coli-derived products",
        "  Not pregnant",
        "  Fertile patients must use effective contraception",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy:",
        "  Not specified",
        "  Chemotherapy:",
        "  At least 4 weeks since prior chemotherapy",
        "  No prior doxorubicin of total dose exceeding 240 mg/m^2",
        "  No prior paclitaxel of total dose of at least 750 mg/m^2",
        "  No more than 12 months since prior conventional-dose adjuvant chemotherapy",
        "  Endocrine therapy:",
        "  At least 4 weeks since prior hormonal therapy",
        "  Radiotherapy:",
        "  At least 4 weeks since prior radiotherapy",
        "  No prior radiation to the left chest wall",
        "  Surgery:",
        "Not specified"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Five-Year Relapse-free Survival",
        "  RFS events included death or disease recurrence. Patients who did not experience disease recurrence or death were censored at the date of last follow-up. Survival rates were estimates using the Kaplan-Meier method.",
        "  Time frame: Five years",
        "Results 1: ",
        "  Arm/Group Title: Arm I (ACT)",
        "  Arm/Group Description: Patients receive 41.25 mg/m2 of doxorubicin IV over 24 hours on days -9 to -6, 100 mg/kg of cyclophosphamide IV over 2 hours on day -5, and 725 mg/m2 of paclitaxel IV over 24 hours on day -4. PBSC are reinfused on days -2 and 0. G-CSF at 5 ug/kg IV is administered beginning on day 0 and continuing until blood counts recover.",
        "  filgrastim: Given IV or subcutaneously",
        "  cyclophosphamide: Given IV",
        "  doxorubicin hydrochloride: Given IV",
        "  paclitaxel: Given IV",
        "  peripheral blood stem cell transplantation: Patients receive autologous peripheral blood stem cells",
        "  Overall Number of Participants Analyzed: 21",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  47        (24 to 67)",
        "Results 2: ",
        "  Arm/Group Title: Arm II (STAMP V)",
        "  Arm/Group Description: Patients receive cyclophosphamide 1.5 g/m2/day IV, carboplatin 200 mg/m2/day IV, and thiotepa 125 mg/m2/day IV over 24 hours on days -7 to -4. PBSC are reinfused on day -2 and 0 and G-CSF at 5ug/kg IV is administered as in arm I.",
        "  filgrastim: Given IV or subcutaneously",
        "  carboplatin: Given IV",
        "  cyclophosphamide: Given IV",
        "  thiotepa: Given IV",
        "  peripheral blood stem cell transplantation: Patients receive autologous peripheral blood stem cells",
        "  Overall Number of Participants Analyzed: 51",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  55        (41 to 68)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/21 (0.00%)",
        "Adverse Events 2:",
        "  Total: "
    ]
}